Consistent with this, NLRP3 deficiency or IL-1 inhibition is beneficial in mouse models of these diseases and type 2 diabetic patients treated with anti-IL-1 therapy display improvements in glucose control and markers of systemic inflammation (Esser et al., 2014). This evidence concerns the gene IL1A and hyperinsulinemic hypoglycemia, familial, 4.